2022 AIM Physician and
Investigator Conference
May 21 – 22, 2022
Salt Lake City, Utah
Hosted by ARUP Laboratories
Overview
The American Initiative in Mast Cell Diseases (AIM) is pleased to announce the 2022 AIM Physician and Investigator Conference, taking place in Salt Lake City May 21-22, 2022. This conference will highlight scientific and clinical discoveries in mast cell disease, as well as clinical trials and newly developed national treatment guidelines. The program will include a roster of world-renowned speakers, a laboratory workshop, an engaging poster session, and opportunities to network. We anticipate more than 125 physicians and researchers to attend from around the world.
The 2022 conference will build upon the success of the inaugural event in 2019 at Stanford University and the second conference which was hosted virtually by ARUP Laboratories in Salt Lake City in May of 2021. As a result of these 2 conferences, AIM has established a network of more than 20 Reference Centers and Centers of Excellence for diagnostic and specialty care expertise.
Registration will be limited to physicians and researchers; there is no registration fee to attend.
Pharmaceutical representatives will have limited attendance, based on sponsorship. Please review opportunities to sponsor or exhibit at the conference.
AIM is committed to providing a safe and healthy atmosphere for our guests. The AIM Committee will be evaluating COVID-19 recommendations from the local, state, and federal health authorities and adjust safety measures or the meeting format as needed.
Schedule of Events
ARUP Laboratories and the University of Utah
Kristin Karner, ARUP Laboratories and the University of Utah
Sabine Hellwig, ARUP Laboratories
David Ng, ARUP Laboratories and the University of Utah
Olivia Tuiono, ARUP Laboratories
Anton Rets, ARUP Laboratories and the University of Utah
Shuttle departure from the Little America Lobby at 16:30
Professor Dr. Peter Valent, Medical University of Vienna
Lawrence Schwartz, Virginia Commonwealth University
Tina Schaller, University Medical Center Augsburg
Dan Dwyer, Brigham and Women’s Hospital, Harvard Medical School
George Caughey, University of California at San Francisco
Michael Deininger, Medical College of Wisconsin
Alberto Orfao, University of Salamanca CSIC-USAL
Tracy George, ARUP Laboratories and the University of Utah
Jason Hornick, Brigham and Women’s Hospital, Harvard Medical School
Olga Pozdnyakova, Brigham and Women’s Hospital, Harvard Medical School
Jonathan Lyons, National Institutes of Health
Peter Novak, Brigham and Women’s Hospital, Harvard Medical School
Matt Giannetti, Brigham and Women’s Hospital, Harvard Medical School
Mariana Castells, Brigham and Women’s Mastocytosis Center, Harvard Medical School
(non-CME activity)
Chairs: Pankit Vachhani and Prithviraj Bose
Clayton Rische, Northwestern University
Irina Maric, National Institutes of Health
Deepti Radia, Guy’s and St. Thomas’ Hospitals
Chairs: Jason Hornick and Deepti Radia
Olga Pozdnyakova, Brigham and Women’s Hospital, Harvard Medical School
Anton Rets, ARUP Laboratories and the University of Utah
Stephanie Lee, University of Toronto/St. Michael’s Hospital and Anne Tierens, Princess Margaret Cancer Centre
Matthew Hamilton, Brigham and Women’s Hospital, Harvard Medical School
Melody Carter, National Institutes of Health
Jennifer Nicoloro-SantaBarbara, Brigham and Women’s Hospital, Harvard Medical School
Karin Hartmann, University of Basel
Cem Akin, University of Michigan
Andreas Reiter, University Hospital Mannheim, Heidelberg University
Jason Gotlib, Stanford University School of Medicine/Stanford Cancer Institute
(non-CME activity)
(non-CME activity)
Alexandra Malinowski, Cogent Biosciences
Mikael Rinne, Blueprint Medicines
Brad Youngblood, Allakos
(additional information forthcoming)
Accreditation: The University Of Utah School Of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit: The University of Utah School of Medicine designates this Live activity for a maximum of 16.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nondiscrimination and Disability Accommodation Statement: The University of Utah does not exclude, deny benefits to or otherwise discriminate against any person on the basis of race, color, national origin, sex, disability, age, veteran’s status, religion, gender identity/expression, genetic information, or sexual orientation in admission to or participation in its programs and activities. Reasonable accommodations will be provided to qualified individuals with disabilities upon request, with reasonable notice. Requests for accommodations or inquiries or complaints about University nondiscrimination and disability/access policies may be directed to the Director, OEO/AA, Title IX/Section 504/ADA Coordinator, 201 S President’s Circle, RM 135, Salt Lake City, UT 84112, 801-581-8365 (Voice/TTY), 801-585-5746 (Fax).
About the Area
Salt Lake City, Utah was selected as the venue for the AIM Conference as it is the home of ARUP Laboratories and the University of Utah. ARUP Laboratories, a nonprofit corporation affiliated with the University of Utah, is a leading reference laboratory in the United States and one of the few laboratories offering state-of-the-art testing for mast cell diseases. In addition, the university has an excellent reputation for cutting-edge basic research and translational science. Salt Lake City and the surrounding area is one of the fastest-growing areas in the United States featuring an international airport, a vibrant downtown with many restaurants and activities from which to choose, and several national parks within easy driving distance.
Sponsorship &
Exhibit Opportunities
Please join us in advancing research, treatment, and education related to mastocytosis and associated mast cell diseases.
The American Initiative in Mast Cell Diseases (AIM) is pleased to announce the 2022 AIM Physician and Investigator Conference. This conference will highlight scientific and clinical discoveries in mast cell disease, as well as clinical trials and newly developed national treatment guidelines. The program will include a roster of world-renowned speakers, a laboratory workshop, an engaging poster session, and opportunities to network. We anticipate the attendance of more than 125 physicians and researchers from around the world.
Our 2022 conference will build upon the success of the inaugural event in 2019 at Stanford University and the second conference, which was hosted virtually by ARUP Laboratories in Salt Lake City in May 2021. As a result of these two conferences, AIM has established a network of more than 20 Reference Centers and Centers of Excellence for diagnostic and specialty care expertise.
We invite you to become a conference sponsor. Please review the sponsorship opportunities and let us know if we can provide additional information or answer any questions. We are eager to partner with you to identify a sponsorship opportunity that aligns with your interests.
Please contact us for more information on sponsorship opportunities.
Sincerely,
